Dizal's US first; now what?
Zegfrovy is approved in a best-case setting, but Dizal has no US presence.
Zegfrovy is approved in a best-case setting, but Dizal has no US presence.
Lynozyfic could have an edge over rival BCMA-targeting bispecifics.
Satri-cel is filed for gastric cancer approval in China.
Astra/Daiichi have trumped Gilead’s Trodelvy with a lung cancer approval.
When your investment case breaks down, why not just do the decent thing?
Ibtrozi breezes through FDA review and gives Nuvation its first approval.